S 14506 hydrochloride

Discontinued Product

S 14506 hydrochloride (Cat. No. 1771) has been withdrawn from sale for commercial reasons.
Description: Highly potent 5-HT1A agonist; displays unique binding mechanism
Chemical Name: 4-Fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride
Purity: ≥99% (HPLC)
Citations (1)
Literature (3)

Biological Activity for S 14506 hydrochloride

S 14506 hydrochloride is a highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo.

Technical Data for S 14506 hydrochloride

M. Wt 443.94
Formula C24H26FN3O2.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 286369-38-8
PubChem ID 131905
Smiles Cl.COC1=CC2=C(C=CC=C2C=C1)N1CCN(CCNC(=O)C2=CC=C(F)C=C2)CC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for S 14506 hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for S 14506 hydrochloride

References are publications that support the biological activity of the product.

Lima et al (1997) Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors. J.Neural Transm. 104 1059 PMID: 9503258

Milligan et al (2001) S 14506: novel receptor coupling at 5-HT1A receptors. Neuropharmacology 40 334 PMID: 11166326

Colpaert et al (1992) S 14506: a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent. Drug Dev.Res. 26 21

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Agonists

Keywords: S 14506 hydrochloride, S 14506 hydrochloride supplier, potent, 5-HT1A, agonists, Serotonin, Receptors, S14506, hydrochloride, 1771, Tocris Bioscience

1 Citation for S 14506 hydrochloride

Citations are publications that use Tocris products. Selected citations for S 14506 hydrochloride include:

Walory et al (2018) Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT1A Receptor Ligands. Int J Mol Sci 19 PMID: 30347827

Reviews for S 14506 hydrochloride

There are currently no reviews for this product. Be the first to review S 14506 hydrochloride and earn rewards!

Have you used S 14506 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.